U.S. markets closed

Solarvest BioEnergy Inc. (SVS.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.10500.0000 (0.00%)
At close: 3:50PM EDT
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.1050
Open0.1050
Bid0.0950 x N/A
Ask0.1050 x N/A
Day's Range0.1000 - 0.1050
52 Week Range0.0150 - 0.1750
Volume49,400
Avg. Volume3,774
Market Cap4.548M
Beta (5Y Monthly)0.52
PE Ratio (TTM)N/A
EPS (TTM)-0.0550
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Solarvest BioEnergy Inc. (CVE:SVS) Insiders Increased Their Holdings
      Simply Wall St.

      Solarvest BioEnergy Inc. (CVE:SVS) Insiders Increased Their Holdings

      We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...

    • FSD Pharma and Solarvest Enhance Commitment to CBD Research Project
      Business Wire

      FSD Pharma and Solarvest Enhance Commitment to CBD Research Project

      FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) ("FSD Pharma") and Solarvest BioEnergy Inc. (TSX-V: SVS) ("Solarvest") (collectively, the "Parties"), are pleased to announce that, further to their press release of May 7, 2019, the Parties have agreed to amendments to the Collaborative Research and Development Agreement (the "Research Agreement") designed to accelerate progress of the research project that Solarvest is carrying out (the "CBD Research Project"). Under the amended Research Agreement, FSD Pharma has agreed to issue additional class B subordinate voting shares ("FSD Shares") to Solarvest, which will enable Solarvest to fund the CBD Research Project. In addition, Solarvest has appointed Dr. Edward J. Brennan, Jr., M.D., FACS ("Dr. Brennan"), currently the President of FSD Pharma’s BioSciences Division, to the board of directors of Solarvest.